Eric P Lefkofsky Sets Out $15.9 Million Plan To Sell Tempus AI Shares

The CEO's proposed sale covers 250,000 shares; four separate accounts recorded $70.2 million of earlier sales.

Share
Eric P Lefkofsky Sets Out $15.9 Million Plan To Sell Tempus AI Shares

Eric P Lefkofsky, CEO and chairman of Tempus AI, which links diagnostic tests to patients' clinical data, plans to sell $15.9 million of company stock. His notice of a planned sale, filed with the SEC Thursday, covers 250,000 Class A shares.

Four Accounts, $70.2 Million Sold

The notice puts the proposed sale alongside 15 completed sales over the past three months. Those transactions totaled 950,000 shares and $70.2 million in gross proceeds across four separately named selling accounts.

Blue Media accounted for 540,000 shares and $40.1 million in proceeds. Gray Media sold 230,000 shares for $17.1 million. Each account recorded four sales, on August 25, September 17, September 22 and October 27, 2026.

Vas.org Foundation sold 150,000 shares for $10.8 million across three transactions, dated August 25, September 22 and October 27, 2026. Lefkofsky Family Foundation recorded four sales on the same dates as Blue Media and Gray Media, totaling 30,000 shares and $2.2 million.

The foundation proceeds belong to those foundation accounts. The combined sales total covers all four accounts.

A Planned Sale Through J.P. Morgan

Lefkofsky plans to use J.P. Morgan Securities as the broker for the proposed transaction. Thursday is the approximate sale date listed in the notice; the transaction remains a planned sale.

Tempus AI shares were up about 8% for the year as of Wednesday's close. Over the past 12 months, they were down about 5% as of Wednesday's close.

The healthcare technology company's diagnostics business offers genomic sequencing and pathology testing. Its data and applications business licenses de-identified patient data and supplies analytics, clinical-trial support and algorithm-based diagnostics to pharmaceutical and biotechnology companies.

Tempus operates five testing laboratories. Its network includes about 700 direct data connections spanning roughly 5,000 hospitals and reaches more than 55% of U.S. oncologists. As of December 31, 2025, its database contained more than 8.6 million de-identified patient records.

Sources

More on Tempus AI

All Tempus AI (TEM) coverage →